Literature DB >> 26822433

MicroRNA-29 regulates high-glucose-induced apoptosis in human retinal pigment epithelial cells through PTEN.

Xiaohui Lin1, Xiyuan Zhou2, Danning Liu1, Lixia Yun3, Lina Zhang3, Xiaohai Chen3, Qinghe Chai3, Langen Li3.   

Abstract

Hyperglycemia or high-glucose (HG)-induced apoptosis in human retinal pigment epithelial (RPE) cells is a characteristic process in diabetic retinopathy. In our study, we examined whether microRNA-29 (miR-29) may regulate HG-induced RPE cell apoptosis. Human RPE cell line, ARPE-19 cells, was treated with various high concentration of glucose in vitro. HG-induced RPE cell apoptosis was examined by terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) assay and miR-29 gene expression by quantitative RT-PCR (qRT-PCR). miR-29 was then downregulated in RPE cells, and its effect on HG-induced apoptosis was examined by TUNEL assay and western blot assay on caspase-7 protein. Association of miR-29 on its downstream target, PTEN, in HG-induced RPE cell apoptosis was evaluated by dual-luciferase assay and qRT-PCR. PTEN was silenced in RPE cells. The effects of PTEN downregulation on miR-29-mediated HG-induced RPE cell apoptosis were also examined by TUNEL and western blot assays. HG induced significant apoptosis in RPE cells in a dose-dependent manner. miR-29 was upregulated by HG in RPE cells. miR-29 downregulation protected HG-induced apoptosis and reduced the production of caspase-7 protein in RPE cells. PTEN was shown to be directly downregulated by HG and then upregulated by miR-29 downregulation in RPE cells. Small interfering RNA (siRNA)-mediated PTEN downregulation reversed the protective effect of miR-29 downregulation on HG-induced RPE cell apoptosis. This study demonstrates that miR-29, through inverse association of PTEN, plays an important role in the process of HG-induced apoptosis in RPE cells.

Entities:  

Keywords:  Apoptosis; High glucose; PTEN; Retinal pigment epithelial cells; miR-29

Mesh:

Substances:

Year:  2016        PMID: 26822433     DOI: 10.1007/s11626-015-9990-z

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  21 in total

1.  Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro.

Authors:  J Winer; C K Jung; I Shackel; P M Williams
Journal:  Anal Biochem       Date:  1999-05-15       Impact factor: 3.365

Review 2.  Role of microRNAs in the modulation of diabetic retinopathy.

Authors:  Rodolfo Mastropasqua; Lisa Toto; Francesco Cipollone; Donato Santovito; Paolo Carpineto; Leonardo Mastropasqua
Journal:  Prog Retin Eye Res       Date:  2014-08-14       Impact factor: 21.198

3.  Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease.

Authors:  C H Kwon; X Zhu; J Zhang; L L Knoop; R Tharp; R J Smeyne; C G Eberhart; P C Burger; S J Baker
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

4.  Altered microRNA expression profiles in retinas with diabetic retinopathy.

Authors:  Jin-hui Wu; Yu Gao; An-jing Ren; Shi-hong Zhao; Ming Zhong; Ya-jun Peng; Wei Shen; Ming Jing; Lin Liu
Journal:  Ophthalmic Res       Date:  2011-12-07       Impact factor: 2.892

5.  PTEN regulates retinal interneuron morphogenesis and synaptic layer formation.

Authors:  Kiyo Sakagami; Bryan Chen; Steven Nusinowitz; Hong Wu; Xian-Jie Yang
Journal:  Mol Cell Neurosci       Date:  2011-12-04       Impact factor: 4.314

6.  Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study.

Authors:  Lei Kong; Junjie Zhu; Wenxia Han; Xiuyun Jiang; Min Xu; Yue Zhao; Qiongzhu Dong; Zengfen Pang; Qingbo Guan; Ling Gao; Jiajun Zhao; Lei Zhao
Journal:  Acta Diabetol       Date:  2010-09-21       Impact factor: 4.280

7.  MicroRNA expression in human retinal pigment epithelial (ARPE-19) cells: increased expression of microRNA-9 by N-(4-hydroxyphenyl)retinamide.

Authors:  R Krishnan Kutty; William Samuel; Cynthia Jaworski; Todd Duncan; Chandrasekharam N Nagineni; Nalini Raghavachari; Barbara Wiggert; T Michael Redmond
Journal:  Mol Vis       Date:  2010-08-04       Impact factor: 2.367

Review 8.  Diabetic retinopathy: pathogenesis, clinical grading, management and future developments.

Authors:  L Z Heng; O Comyn; T Peto; C Tadros; E Ng; S Sivaprasad; P G Hykin
Journal:  Diabet Med       Date:  2013-06       Impact factor: 4.359

9.  MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus.

Authors:  Dwi Setyowati Karolina; Arunmozhiarasi Armugam; Subramaniam Tavintharan; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

10.  Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats.

Authors:  Viviane A O Silva; Anna Polesskaya; Thaís A Sousa; Vani M A Corrêa; Nayara Delgado André; Rosana I Reis; Isis C Kettelhut; Annick Harel-Bellan; Fernando L De Lucca
Journal:  Mol Vis       Date:  2011-08-18       Impact factor: 2.367

View more
  11 in total

1.  Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.

Authors:  Penn Muluhngwi; Abirami Krishna; Stephany L Vittitow; Joshua T Napier; Kirsten M Richardson; Mackenzie Ellis; Justin L Mott; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

2.  Expression and regulation of microRNA-29a and microRNA-29c in early diabetic rat cataract formation.

Authors:  Ying Sun; Chun-Mei Lu; Zhen Song; Ke-Ke Xu; Shu-Bin Wu; Zhi-Jian Li
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

3.  A therapeutic approach towards microRNA29 family in vascular diabetic complications: A boon or curse?

Authors:  Aishwarya P Dasare; Piyush Gondaliya; Akshay Srivastava; Kiran Kalia
Journal:  J Diabetes Metab Disord       Date:  2019-05-11

4.  miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions.

Authors:  Eun-Ah Ye; Jena J Steinle
Journal:  Vision Res       Date:  2017-04-26       Impact factor: 1.886

Review 5.  Molecular biomarkers in diabetes mellitus (DM).

Authors:  Seyed Mohsen Aghaei Zarch; Masoud Dehghan Tezerjani; Mehrdad Talebi; Mohammad Yahya Vahidi Mehrjardi
Journal:  Med J Islam Repub Iran       Date:  2020-04-01

6.  Combination of leflunomide and benazepril reduces renal injury of diabetic nephropathy rats and inhibits high-glucose induced cell apoptosis through regulation of NF-κB, TGF-β and TRPC6.

Authors:  Huili Li; Yuanyuan Wang; Zhangqing Zhou; Fang Tian; Huanhuan Yang; Juzhen Yan
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

7.  Long non-coding RNA VIM Antisense RNA 1 (VIM-AS1) sponges microRNA-29 to participate in diabetic retinopathy.

Authors:  Feng Zeng; Gang Luo; Yamei Lu; Zhaotian Zhang; Yuanqing Zhou; Yonging Chen; Zhiyan Zhou
Journal:  Acta Diabetol       Date:  2020-05-23       Impact factor: 4.280

8.  Pax5 regulates B cell immunity by promoting PI3K signaling via PTEN down-regulation.

Authors:  Lesly Calderón; Karina Schindler; Stephen G Malin; Alexandra Schebesta; Qiong Sun; Tanja Schwickert; Chiara Alberti; Maria Fischer; Markus Jaritz; Hiromi Tagoh; Anja Ebert; Martina Minnich; Adrian Liston; Luisa Cochella; Meinrad Busslinger
Journal:  Sci Immunol       Date:  2021-07-23

Review 9.  Roles of miRNAs and long noncoding RNAs in the progression of diabetic retinopathy.

Authors:  Qiaoyun Gong; Guanfang Su
Journal:  Biosci Rep       Date:  2017-11-29       Impact factor: 3.840

10.  miR‑29b promotes the osteogenic differentiation of mesenchymal stem cells derived from human adipose tissue via the PTEN/AKT/β‑catenin signaling pathway.

Authors:  Tian Xia; Shuanghai Dong; Jiwei Tian
Journal:  Int J Mol Med       Date:  2020-05-22       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.